Hyderabad: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) (“Aurobindo”) today announced its consolidated financial results for the quarter and year ended March 31, 2026.
Key Highlights
• Revenue from Operations increased by 5.6% YoY to INR 8,853 Cr with growth across businesses
• Company’s European business achieved a significant milestone of crossing €1bn+ in revenues in FY26, for the quarter revenues increased by 30.2% YoY to INR 2,795 Cr (EUR 261 million)
• Growth Markets revenue increased by 24.7% YoY to INR 980 Cr (USD 107 million)
• ARV revenue increased by 6.4% YoY to INR 328 Cr (USD 36 million)
• Research & Development (R&D including depreciation) spend was INR 400 Cr, 4.5% of revenues
• Received final approval for 9 ANDAs from the USFDA
• Net Profit for the quarter stood at INR 921 Cr
• Strong net cash position as on 31-Mar-26 after payment for acquisition of Khandelwal laboratories (non-oncology) business at USD 317mn
• Free Cashflows generated $35mn during the quarter
• Basic & Diluted EPS stood at INR 15.86 per share
Nithyananda Reddy, Vice-Chairman and Managing Director, said: “We are encouraged by our performance for the quarter and the year, reflecting the resilience of our business model and the strength of our extensive product portfolio. Consistent volumes coupled with improved operating efficiencies, and disciplined execution have contributed positively to our results. With ongoing investments in capacity expansion and the stabilization of recently commercialized facilities, we remain confident in our ability to support sustainable growth and create long-term value for our stakeholders.”
